Last Price$59.76.8%
Market Cap$3,532.4M
LTM Return on Equity (ROE)
45.6%
5Y avg
(19.3%)
Biotechnology industry
median
(53.8%)
Stock quality & Intrinsic value
7/10
(0.7%) overvalued
Protagonist Therapeutics, Inc. Return on Equity (ROE)
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | (139.2%) | (169.3%) | (76.5%) | (35.5%) | (33.4%) | (80.2%) | (36.8%) | (43.3%) | 107.6% | 78.9% | 54.4% |
Overvalued or undervalued?
Check the intrinsic value for PTGX
and see if it's the right time to invest.
Protagonist Therapeutics, Inc. (PTGX) Return on Equity (ROE) comparison analysis
General
LTM Return on Equity (ROE)
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Protagonist Therapeutics, Inc.PTGX
45.6%
624.1%
N/A
63.3%
Median Peer Set
(3.4%)
14.8%
(19.3%)
7.5%
United Therapeutics CorporationUTHR
19.1%
23.6%
25.7%
41.5%
Regeneron Pharmaceuticals, Inc.REGN
13.7%
8.3%
10.4%
31.1%
Royalty Pharma plcRPRX
12.9%
(3.8%)
(43.7%)
37.9%
BioMarin Pharmaceutical Inc.BMRN
7.7%
18.0%
139.3%
15.0%
Vertex Pharmaceuticals IncorporatedVRTX
(3.3%)
11.7%
N/A
(4.9%)
BioNTech SEBNTX
(3.5%)
(77.4%)
(89.7%)
24.4%
argenx SEARGX
(4.8%)
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
(25.3%)
73.7%
467.1%
(35.9%)
Summit Therapeutics Inc.SMMT
(53.5%)
N/A
(68.7%)
N/A
Alnylam Pharmaceuticals, Inc.ALNY
(559.4%)
23.0%
(38.6%)
(12.4%)
PTGX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 20.1 0.0% | 30.9 54.1% | 0.2 (99.3%) | 28.6 12,293.1% | 27.4 (4.4%) | 26.6 (2.8%) | 60.0 125.7% | 434.4 624.1% |
| Cost of Goods Sold (COGS) | 0.0 | 0.2 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 2.8 | 1.0 | 0.0 | 0.0 |
% margin | 0.0 0.0% | (0.2) 0.0% | (0.3) 0.0% | 20.1 100.0% | 30.9 100.0% | 0.2 100.0% | 28.6 100.0% | 24.6 89.9% | 25.5 96.1% | 60.0 100.0% | 434.4 100.0% |
| Operating Expenses | 9.3 | 14.8 | 32.7 | 58.0 | 73.2 | 80.8 | 93.1 | 153.2 | 158.0 | 153.7 | 181.6 |
| Research & Development Expenses (R&D) | 7.5 | 11.8 | 25.7 | 46.2 | 59.5 | 65.0 | 74.5 | 126.0 | 126.2 | 120.2 | 138.1 |
| Selling, General & Administrative Expenses (SG&A) | 1.9 | 3.0 | 7.0 | 11.8 | 13.7 | 15.7 | 18.6 | 27.2 | 31.7 | 33.5 | 43.5 |
% margin | (9.3) 0.0% | (14.8) 0.0% | (32.7) 0.0% | (37.9) (188.9%) | (42.3) (136.7%) | (80.5) (34,857.6%) | (64.5) (225.4%) | (125.8) (460.0%) | (131.4) (494.2%) | (93.7) (156.1%) | 252.8 58.2% |
| Interest Income | 0.0 | 0.0 | 0.2 | 0.9 | 2.6 | 2.8 | 0.9 | 0.4 | 4.1 | 14.9 | 26.3 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | (11.1) | (14.9) | (37.2) | (37.0) | (39.7) | (77.9) | (64.8) | (125.6) | (127.4) | (79.0) | 279.4 |
% effective tax rate | 1.8 (15.8%) | 0.1 (0.4%) | 4.2 (11.2%) | (0.4) 1.1% | (0.8) 2.0% | (0.7) 0.9% | 1.3 (2.0%) | (2.9) 2.3% | (4.0) 3.1% | 0.0 0.0% | 4.2 1.5% |
% margin | (11.1) 0.0% | (14.9) 0.0% | (37.2) 0.0% | (37.0) (184.2%) | (38.9) (125.9%) | (77.2) (33,414.3%) | (66.2) (231.1%) | (122.6) (448.2%) | (123.4) (464.3%) | (79.0) (131.6%) | 275.2 63.3% |
| EPS | (1.88) | (2.52) | (5.72) | (2.09) | (1.74) | (2.98) | (1.92) | (2.65) | (2.52) | (1.39) | 4.47 |
| Diluted EPS | (1.88) | (2.52) | (5.72) | (2.09) | (1.74) | (2.98) | (1.92) | (2.65) | (2.52) | (1.39) | 4.23 |
% margin | (9.1) 0.0% | (14.5) 0.0% | (32.3) 0.0% | (36.6) (182.2%) | (39.2) (126.7%) | (78.3) (33,898.7%) | (63.7) (222.4%) | (123.1) (449.9%) | (131.4) (494.2%) | (90.3) (150.6%) | 252.8 58.2% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Protagonist Therapeutics, Inc.'s Return on Equity (ROE)?
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 45.6%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Return on Equity (ROE) for Protagonist Therapeutics, Inc. have been (2.8%) over the past three years, and (20.3%) over the past five years.
2) Is Protagonist Therapeutics, Inc.'s Return on Equity (ROE) Good?
As of today, Protagonist Therapeutics, Inc.'s Return on Equity (ROE) is 45.6%, which is higher than industry median of (53.8%). It indicates that Protagonist Therapeutics, Inc.'s Return on Equity (ROE) is Good.